MORPHABOND ER Drug Patent Profile
When do Morphabond Er patents expire, and what generic alternatives are available?
Morphabond Er is a drug marketed by Ohemo Life and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
The generic ingredient in MORPHABOND ER is morphine sulfate. There is one drug master file entry for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Morphabond Er
A generic version of MORPHABOND ER was approved as morphine sulfate by HOSPIRA on September 30th, 1992.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MORPHABOND ER?
- What are the global sales for MORPHABOND ER?
- What is Average Wholesale Price for MORPHABOND ER?
Summary for MORPHABOND ER
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 8 |
| Patent Applications: | 3,989 |
| Drug Prices: | Drug price information for MORPHABOND ER |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for MORPHABOND ER |
| DailyMed Link: | MORPHABOND ER at DailyMed |
Paragraph IV (Patent) Challenges for MORPHABOND ER
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| MORPHABOND ER | Extended-release Tablets | morphine sulfate | 15 mg, 30 mg, 60 mg and 100 mg | 206544 | 1 | 2019-01-28 |
US Patents and Regulatory Information for MORPHABOND ER
MORPHABOND ER is protected by two US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ohemo Life | MORPHABOND ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 206544-001 | Oct 2, 2015 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Ohemo Life | MORPHABOND ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 206544-004 | Oct 2, 2015 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Ohemo Life | MORPHABOND ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 206544-002 | Oct 2, 2015 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for MORPHABOND ER
See the table below for patents covering MORPHABOND ER around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2008286914 | ⤷ Start Trial | |
| Australia | 2009282376 | ⤷ Start Trial | |
| Australia | 2015200009 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch